LDLR and atherosclerosis: Moreover, there is a positive correlation between PCSK9 (proprotein convertase subtilisin/kexin type 9), a regulator of hepatocyte LDL receptor, and PTX3, confirming once again its clinical use in assessing atherosclerosis [91].